These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area. Clemens JD; Sack DA; Rao MR; Chakraborty J; Khan MR; Kay B; Ahmed F; Banik AK; van Loon FP; Yunus M J Infect Dis; 1992 Nov; 166(5):1029-34. PubMed ID: 1402014 [TBL] [Abstract][Full Text] [Related]
23. Update on CVD 103-HgR single-dose, live oral cholera vaccine. McCarty J; Bedell L; De Lame PA; Cassie D; Lock M; Bennett S; Haney D Expert Rev Vaccines; 2022 Jan; 21(1):9-23. PubMed ID: 34775892 [TBL] [Abstract][Full Text] [Related]
24. Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh. Leung DT; Uddin T; Xu P; Aktar A; Johnson RA; Rahman MA; Alam MM; Bufano MK; Eckhoff G; Wu-Freeman Y; Yu Y; Sultana T; Khanam F; Saha A; Chowdhury F; Khan AI; Charles RC; Larocque RC; Harris JB; Calderwood SB; Kovác P; Qadri F; Ryan ET Clin Vaccine Immunol; 2013 Jun; 20(6):780-8. PubMed ID: 23515016 [TBL] [Abstract][Full Text] [Related]
25. Emerging Concepts in Cholera Vaccine Design. Sit B; Fakoya B; Waldor MK Annu Rev Microbiol; 2022 Sep; 76():681-702. PubMed ID: 35759873 [TBL] [Abstract][Full Text] [Related]
26. Longitudinal analysis of human humoral responses after vaccination with a live attenuated V. cholerae vaccine. Adekunle O; Dretler A; Kauffman RC; Cho A; Rouphael N; Wrammert J PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009743. PubMed ID: 34478460 [TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days. Xian TH; Sinniah K; Yean CY; Krishnamoorthy V; Bahari MB; Ravichandran M; Prabhakaran G BMC Immunol; 2020 May; 21(1):29. PubMed ID: 32450807 [TBL] [Abstract][Full Text] [Related]
33. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Levine MM; Kaper JB; Black RE; Clements ML Microbiol Rev; 1983 Dec; 47(4):510-50. PubMed ID: 6363898 [TBL] [Abstract][Full Text] [Related]
34. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509 [TBL] [Abstract][Full Text] [Related]
35. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009. Chowdhury MI; Sheikh A; Qadri F Expert Rev Vaccines; 2009 Dec; 8(12):1643-52. PubMed ID: 19943759 [TBL] [Abstract][Full Text] [Related]
36. Scalable production and immunogenicity of a cholera conjugate vaccine. Jeon S; Kelly M; Yun J; Lee B; Park M; Whang Y; Lee C; Halvorsen YD; Verma S; Charles RC; Harris JB; Calderwood SB; Leung DT; Bhuiyan TR; Qadri F; Kamruzzaman M; Cho S; Vann WF; Xu P; Kováč P; Ganapathy R; Lynch J; Ryan ET Vaccine; 2021 Nov; 39(47):6936-6946. PubMed ID: 34716040 [TBL] [Abstract][Full Text] [Related]
37. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Viret JF; Favre D; Wegmüller B; Herzog C; Que JU; Cryz SJ; Lang AB Infect Immun; 1999 Jul; 67(7):3680-5. PubMed ID: 10377160 [TBL] [Abstract][Full Text] [Related]
38. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae. Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of enteric-coated tablets as a whole cell inactivated vaccine candidate against Vibrio cholerae. Fernández S; Año G; Castaño J; Pino Y; Uribarri E; Riverón LA; Cedré B; Valmaseda T; Falero G; Pérez JL; Infante JF; García LG; Solís RL; Sierra G; Talavera A Travel Med Infect Dis; 2013; 11(2):103-9. PubMed ID: 23492079 [TBL] [Abstract][Full Text] [Related]
40. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Viret JF; Dietrich G; Favre D Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]